Message #18 From:
NewsBot Date: December 27, 2006 06:30:00 AM
SPRX News SpectRx, Inc. Reports Third Quarter 2006 Results
NORCROSS, Ga.--(BUSINESS WIRE)--SpectRx, Inc. (OTCBB: SPRX) today announced operating results for the
third quarter and nine months ended September 30, 2006.
Revenue for the three months ended September 30, 2006, was $457,000
versus $174,000 for the same period last year. For the nine months ended
September 30, 2006, revenue was $791,000 versus $812,000 for the same
period last year. The increase in revenue for the quarter was due to an
increase in our contract revenue for our ISF technology.
The net loss attributable to common stockholders for the third quarter
of 2006 was $1.2 million, or $0.10 per share, compared with a net loss
attributable to common stockholders of $1.2 million, or $0.11 per share,
in the comparable quarter of 2005.
For the first nine months of this year, the net loss attributable to
common stockholders was $4.1 million, or $0.35 per share, compared with
a net loss attributable to common stockholders of $4.0 million, or $0.35
per share, for the first nine months of 2005.
About SpectRx
SpectRx, Inc. (OTCBB: SPRX) is a diabetes management company developing
and providing innovative solutions for insulin delivery and glucose
monitoring. SpectRx markets the SimpleChoice®
line of innovative diabetes management products, which include insulin
pump disposable supplies. SpectRx also plans to develop a consumer
device for continuous glucose monitoring. The company is commercializing
its non-invasive cervical cancer detection technology through its
subsidiary Guided Therapeutics, Inc. For more information, visit SpectRx’s
web sites at spectrx.com, mysimplechoice.com and guidedtherapeutics.com.
“Safe Harbor”
Statement under the Private Securities Litigation Reform Act of 1995. A
number of the matters and subject areas discussed in this news release
that are not historical or current facts deal with potential future
circumstances and developments. The discussion of such matters and
subject areas is qualified by the inherent risks and uncertainties
surrounding future expectations generally and also may materially differ
from SpectRx’s actual future experience
involving any of or more of such matters and subject areas. Such risks
and uncertainties include: the early stage of products in development,
the uncertainty of market acceptance of products, the uncertainty of
development or effectiveness of distribution channels, the intense
competition in the medical device industry, the uncertainty of capital
to develop products, the uncertainty of regulatory approval of products,
dependence on licensed intellectual property, as well as those that are
more fully described from time to time under the heading “Risk
Factors” in SpectRx’s
reports filed with the SEC, including SpectRx’s
Annual Report on Form 10-KSB for the fiscal year ended December 31,
2005, as amended, and subsequent quarterly reports.
